Procurement Summary
Country: USA
Summary: In-Vivo Efficacy Study of a Niclosamide Prodrug in a Golden Syrian Hamster Model of Sars-Cov-2 (Covid-19)
Deadline: 25 Feb 2021
Posting Date: 20 Feb 2021
Other Information
Notice Type: Tender
TOT Ref.No.: 50434786
Document Ref. No.: 75N95021Q00075
Competition: ICB
Financier: Self Financed
Purchaser Ownership: -
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_details
Login to see detailsTender Details
In-vivo Efficacy Study of a Niclosamide Prodrug in a Golden Syrian Hamster Model of SARS-CoV-2 (COVID-19)
Active Contract Opportunity
Notice ID : 75N95021Q00075
Related Notice
Department/Ind. Agency : HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-tier : NATIONAL INSTITUTES OF HEALTH
Office : NATIONAL INSTITUTES OF HEALTH NIDA
General Information
Contract Opportunity Type: Combined Synopsis/Solicitation (Original)
All Dates/Times are: (UTC-05:00) EASTERN STANDARD TIME, NEW YORK, USA
Original Published Date: Feb 19, 2021 09:51 am EST
Original Date Offers Due: Feb 25, 2021 09:00 am EST
Inactive Policy: Manual
Original Inactive Date: Mar 06, 2021
Initiative: None
Classification
Original Set Aside: Total Small Business Set-Aside (FAR 19.5)
Product Service Code: Q301 - MEDICAL- LABORATORY TESTING
NAICS Code: 325414 - Biological Product (except Diagnostic) Manufacturing
Place of Performance:
Description
The National Center for Advancing Translational Sciences (NCATS) is a part of the National Institutes of Health (NIH), with a mission to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions.
Niclosamide is an old anthelminthic drug. Its potential as an anti-cancer and anti-viral agent has been demonstrated in numerous recent publicati...
Documents
Tender Notice